Efficacy of Lanreotide to Treat Neuroendocrine Tumors

0 Views

07/09/23

Arvind Dasari, MD, of University of Texas MD Anderson Cancer Center summarizes the efficacy data of Somatuline Depot (lanreotide) to treat patients with neuroendocrine tumors.

Lanreotide has a high affinity for somatostatin receptors 2 and 5. Like somatostatin, lanreotide is an inhibitor of various endocrine, neuroendocrine, exocrine, and paracrine functions.

Lanreotide is indicated for:
• the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/orradiotherapy
• the treatment of patients with unresectable, well-or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.